SPRC - Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments | Benzinga
SciSparc Ltd. (NASDAQ:SPRC) announced on Friday that it has enrolled the first patient in the company's clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder.
SCI-210 is a combination of CBD and CannAmide – the company's Palmitoylethanolamide – which is designed to alleviate ASD symptoms.
Why It Matters
"The enrollment of our first patient means that we are moving towards a new frontier in the treatment of ASD," said Oz Adler, the company's CEO. "We are pleased to enroll the first patient in the trial, which will further our understanding of the potential role of SCI-210 in the treatment of ASD symptoms.”
The Israel-based SciSparc said it will enroll 60 participants between the ages of 5 and 18, for 20 weeks. The goal of the trial, which is designed in consultation with the National Autism Research Center, ...